Agentes anti TNF: Evidencia en nuevas indicaciones

Review of the published literature has been undertaken in reference to the use of drugs that block the tumoral necrosis factor alpha (TNF-a.) in off-label indications. The higher degree of evidence is observed in pathologies like psoriasis, psoriatic arthritis and ankylosing spondylitis. In others (Wegener's granulomatosis, sarcoidosis, Sjogren's syndrome, graft versus host disease, Behcet's syndrome), due to the lack of controlled studies, the degree of evidence is lower. Therapy with anti-TNF drugs creates hope in the treatment of pathologies with higher degree of evidence and in cases resistant to conventional therapy for which it does not exist a totally efficient therapy. Nonetheless, due to the lack of knowledge about the long-term adverse effects of this type of therapy, it is necessary an active pharmacosurveillance work to use them with a high degree of safety and efficacy